Idiosyncratic reactions and metabolism of sulfur-containing drugs

Bibliography

• Park BK, Pirmohamed M, Kitteringham NR. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem Res Toxicol 1998;11:969-88
   PubMed Web of Science ®Google Scholar
• Royer RJ. Mechanism of action of adverse drug reactions: an overview. Pharmacoepidemiol Drug Saf 1997;6:S43-50
   PubMed Web of Science ®Google Scholar
• Lammert C, Einarsson S, Saha C, Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008;47:2003-9
   PubMed Web of Science ®Google Scholar
• Friedmann PS, Lee MS, Friedmann AC, Barnetson RS. Mechanisms in cutaneous drug hypersensitivity reactions. Clin Exp Allergy 2003;33:861-72
   PubMed Web of Science ®Google Scholar
• Obermayer-Straub P, Manns M. Immunological mechanisms in liver injury. In: Kaplowitz N, DeLeve L, editors. Drug-Induced Liver Disease. Marcel Dekker; New York: 2003. p. 145-9
   Google Scholar
• Ostapowicz G, Fontana RJ, Schiodt FV, Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-54
   PubMed Web of Science ®Google Scholar
• Aster RH. Adverse Drug Reactions Affecting Blood Cells. 196th edition. Springer-Verlag; Berlin Heidelberg: 2010. p. 57-76
   Google Scholar
• Nigen S, Knowles SR, Shear NH. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol 2003;2:278-99
   PubMedGoogle Scholar
• Lasser KE, Allen PD, Woolhandler SJ, Timing of new black box warnings and withdrawals for prescription medications. J Am Med Assoc 2002;287:2215-20
   PubMed Web of Science ®Google Scholar
• Uetrecht J. Role of animal models in the study of drug-induced hypersensitivity reactions. AAPS J 2006;7:E914-21
   PubMed Web of Science ®Google Scholar
• Buchweitz JP, Ganey PE, Bursian SJ, Roth RA. Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy? J Pharmacol Exp Ther 2002;300:460-7
   PubMed Web of Science ®Google Scholar
• Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 2004;17:3-16
   PubMed Web of Science ®Google Scholar
• Kalgutkar AS, Gardner I, Obach RS, A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab 2005;6:161-225
   PubMed Web of Science ®Google Scholar
• Kruhlak NL, Contrera JF, Benz RD, Matthews EJ. Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products. Adv Drug Deliv Rev 2007;59:43-55
   PubMed Web of Science ®Google Scholar
• Uetrecht J. Idiosyncratic drug reactions: past, present, and future. Chem Res Toxicol 2008;21:84-92
   PubMed Web of Science ®Google Scholar
• Ganey PE, Luyendyk JP, Maddox JF, Roth RA. Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem Biol Interact 2004;150:35-51
   PubMed Web of Science ®Google Scholar
• Ju C, Pohl LR. Tolerogenic role of Kupffer cells in immune-mediated adverse drug reactions. Toxicology 2005;209:109-12
   PubMed Web of Science ®Google Scholar
• Roth RA, Luyendyk JP, Maddox JF, Ganey PE. Inflammation and drug idiosyncrasy - Is there a connection? J Pharmacol Exp Ther 2003;307:1-8
   PubMed Web of Science ®Google Scholar
• Bersoff-Matcha SJ, Miller WC, Aberg JA, Sex differences in nevirapine rash. Clin Infect Dis 2001;32:124-9
   PubMed Web of Science ®Google Scholar
• Lucena MI, Andrade RJ, Kaplowitz N, Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009;49:2001-9
   PubMed Web of Science ®Google Scholar
• Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Semin Liver Dis 2009;29:400-11
   PubMed Web of Science ®Google Scholar
• Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. J Am Med Assoc 1988;259:1185-9
   PubMed Web of Science ®Google Scholar
• Gholami K, Shalviri G. Factors associated with preventability, predictability, and severity of adverse drug reactions. Ann Pharmacother 1999;33:236-40
   PubMed Web of Science ®Google Scholar
• Huang Y, Su W, Huang Y, Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 2007;47:128-34
   PubMed Web of Science ®Google Scholar
• Lin HJ, Han CY, Lin BK, Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 1994;4:125-34
   PubMedGoogle Scholar
• Mladosievicova B, Dzurenkova A, Sufliarska S, Carter A. Clinical relevance of thiopurine S-methyltransferase gene polymorphisms. Neoplasma 2011;58:277-82
   PubMed Web of Science ®Google Scholar
• Lang C, Meier Y, Stieger B, Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics 2007;17:47-60
   PubMed Web of Science ®Google Scholar
• Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295-302
   PubMed Web of Science ®Google Scholar
• Thompson RA, Isin EM, Li Y, Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. Chem Biol Interact 2011;192:65-71
   PubMed Web of Science ®Google Scholar
• Smith D, Obach R. Metabolites and safety: what are the concerns, and how should we address them? Chem Res Toxicol 2006;19:1570-9
   PubMed Web of Science ®Google Scholar
• Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045
   PubMed Web of Science ®Google Scholar
• Roujeau JC, Kelly JP, Naldi L, Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7
   PubMed Web of Science ®Google Scholar
• Pleasants RA, Walker TR, Samuelson WM. Allergic reactions to parenteral beta-lactam antibiotics in patients with cystic fibrosis. Chest 1994;106:1124-8
   PubMed Web of Science ®Google Scholar
• Pichler WJ, Naisbitt DJ, Park BK. Immune pathomechanism of drug hypersensitivity reactions. J Allergy Clin Immunol 2011;127:S74-81
   PubMed Web of Science ®Google Scholar
• Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2002;2:301-5
   PubMed Web of Science ®Google Scholar
• Mitchell JR, Jollow DJ, Gillette JR, Brodie BB. Drug metabolism as a cause of drug toxicity. Drug Metab Dispos 1973;1:418-23
   PubMed Web of Science ®Google Scholar
• Pereillo J, Maftouh M, Andrieu A, Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002;30:1288-95
   PubMed Web of Science ®Google Scholar
• Zampaglione N, Hilbert J, Ning J, Disposition and metabolic fate of 14C-quazepam in man. Drug Metab Dispos 1985;13:25-9
   PubMed Web of Science ®Google Scholar
• Dansette PM, Bonierbale E, Minoletti C, Drug-induced immunotoxicity. Eur J Drug Metab Pharmacokinet 1998;23:443-51
   PubMed Web of Science ®Google Scholar
• Tirmenstein MA, Nelson SD. Subcellular binding and effects on calcium homeostasis produced by acetaminophen and a nonhepatotoxic regioisomer, 3'-hydroxyacetanilide, in mouse liver. J Biol Chem 1989;264:9814-19
   PubMed Web of Science ®Google Scholar
• Boelsterli UA, Lim PLK. Mitochondrial abnormalities-a link to idiosyncratic drug hepatotoxicity? Toxicol Appl Pharmacol 2007;220:92-107
   PubMed Web of Science ®Google Scholar
• Mercer AE, Regan SL, Hirst CM, Functional and toxicological consequences of metabolic bioactivation of methapyrilene via thiophene S-oxidation: induction of cell defence, apoptosis and hepatic necrosis. Toxicol Appl Pharmacol 2009;239:297-305
   PubMed Web of Science ®Google Scholar
• Yeung JH, Breckenridge AM, Park BK. Drug protein conjugates–VI. Role of glutathione in the metabolism of captopril and captopril plasma protein conjugates. Biochem Pharmacol 1983;32:3619-25
   PubMed Web of Science ®Google Scholar
• Wilkin JK, Hammond JJ, Kirkendall WM. The captopril-induced eruption. A possible mechanism: cutaneous kinin potentiation. Arch Dermatol 1980;116:902-5
   PubMed Web of Science ®Google Scholar
• Luderer JR, Lookingbill DP, Schneck DW. Captopril-induced skin eruptions. J Clin Pharmacol 1982;22:151-9
   PubMed Web of Science ®Google Scholar
• Freis ED, Materson J, Neal WW. Low-dose captopril for the treatment of mild to moderate hypertension. Hypertension 1983;5:III
   Google Scholar
• Drummer OH, Jarrott B. The disposition and metabolism of captopril. Med Res Rev 1986;6:75-97
   PubMed Web of Science ®Google Scholar
• Berova N, Petkov I, Andreev VC. Treatment of chronic urticaria with a proteinase (kallikrein) inhibitor. Br J Dermatol 1974;90:431-4
   PubMed Web of Science ®Google Scholar
• Coleman JW, Yeung JHK, Roberts DH. Drug-specific antibodies in patients receiving captopril. Br J Clin Pharmacol 1986;22:161-5
   PubMed Web of Science ®Google Scholar
• Kitamura K, Aihara M, Osawa J, Sulfhydryl drug-induced eruption: a clinical and histological study. J Dermatol 1990;17:44-51
   PubMedGoogle Scholar
• Korman NJ, Eyre RW, Zone J, Stanley JR. Drug-induced pemphigus: autoantibodies directed against the pemphigus antigen complexes are present in penicillamine and captopril-induced pemphigus. J Invest Dermatol 1991;96:273-6
   PubMed Web of Science ®Google Scholar
• Anzenbacher P, Anzenbacherova E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 2001;58:737-47
   PubMed Web of Science ®Google Scholar
• Jaffe IA. Adverse effects profile of sulfhydryl compounds in man. Am J Med 1986;80:471-6
   PubMed Web of Science ®Google Scholar
• Irvin JD, Viau JM. Safety profiles of the angiotensin converting enzyme inhibitors captopril and enalapril. Am J Med 1986;81:46-50
   PubMed Web of Science ®Google Scholar
• Stepan AF, Walker DP, Bauman J, Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem Res Toxicol 2011;24:1345-410
   PubMed Web of Science ®Google Scholar
• Gale EAM. Lessons from the glitazones: a story of drug development. Lancet 2001;357:1870-5
   PubMed Web of Science ®Google Scholar
• Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone [1]. N Engl J Med 1998;338:916-17
   PubMed Web of Science ®Google Scholar
• Graham DJ, Green L, Senior JR, Nourjah P. Troglitazone-induced liver failure: a case study. Am J Med 2003;114:299-306
   PubMed Web of Science ®Google Scholar
• Lloyd S, Hayden MJ, Sakai Y, Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors. Chem Biol Interact 2002;142:57-71
   PubMed Web of Science ®Google Scholar
• Alvarez-Sanchez R, Montavon F, Hartung T, Pahler A. Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry. Chem Res Toxicol 2006;19:1106-16
   PubMed Web of Science ®Google Scholar
• Kassahun K, Pearson PG, Tang W, Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem Res Toxicol 2001;14:62-70
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Shibata A, Suzuki M, Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos 1999;27:1260-6
   PubMed Web of Science ®Google Scholar
• Sahi J, Black CB, Hamilton GA, Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos 2003;31:439-46
   PubMed Web of Science ®Google Scholar
• Lehmann JM, McKee DD, Watson MA, The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998;102:1016-23
   PubMed Web of Science ®Google Scholar
• Willson TM, Kliewer SA. PXR, car and drug metabolism. Nat Rev Drug Discov 2002;1:259-66
   PubMed Web of Science ®Google Scholar
• Honma W, Shimada M, Sasano H, Phenol sulfotransferase, ST1A3, as the main enzyme catalyzing sulfation of troglitazone in human liver. Drug Metab Dispos 2002;30:944-9
   PubMed Web of Science ®Google Scholar
• He K, Talaat RE, Pool WF, Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved. Drug Metab Dispos 2004;32:639-46
   PubMed Web of Science ®Google Scholar
• Maniratanachote R, Shibata A, Kaneko S, Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction. Toxicology 2005;216:15-23
   PubMed Web of Science ®Google Scholar
• Smith MT. Mechanisms of troglitazone hepatotoxicity. Chem Res Toxicol 2003;16:679-87
   PubMed Web of Science ®Google Scholar
• Caldwell SH, Hespenheide EE, Redick JA, A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519-25
   PubMed Web of Science ®Google Scholar
• Ong MMK, Latchoumycandane C, Boelsterli UA. Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol Sci 2007;97:205-13
   PubMed Web of Science ®Google Scholar
• Jaeschke H. Troglitazone hepatotoxicity: are we getting closer to understanding idiosyncratic liver injury? Toxicol Sci 2007;97:1-3
   PubMed Web of Science ®Google Scholar
• Nelson SD. Structure Toxicity Relationships - How useful are they in Predicting Toxicities of new Drugs?. 500th edition. Springer-Verlag: 2001. p. 33-43
   Google Scholar
• Lau K, Goldberg M, Stote R, Agus ZS. Renal effects of SKF 62698 (SKF): a new uricosuric diuretic. Clin Res 1976;24
   Google Scholar
• Zimmerman HJ, Lewis JH, Ishak KG, Maddrey WC. Ticrynafen-associated hepatic injury: analysis of 340 cases. Hepatology 1984;4:315-23
   PubMed Web of Science ®Google Scholar
• Neuberger J, Williams R. Immune mechanisms in tienilic acid associated hepatotoxicity. Gut 1989;30:515-19
   PubMed Web of Science ®Google Scholar
• Mansuy D, Dansette PM, Foures C. Metabolic hydroxylation of the thiophene ring: isolation of 5-hydroxy-tienilic acid as the major urinary metabolite of tienilic acid in man and rat. Biochem Pharmacol 1984;33:1429-35
   PubMed Web of Science ®Google Scholar
• Koenigs LL, Peter RM, Hunter AP, Electrospray ionization mass spectrometric analysis of intact cytochrome P450: identification of tienilic acid adducts to P450 2C9. Biochemistry 1999;38:2312-19
   PubMed Web of Science ®Google Scholar
• Homberg JC, Andre C, Abuaf N. A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis. Clin Exp Immunol 1984;55:561-70
   PubMed Web of Science ®Google Scholar
• Lopez-Garcia M, Dansette P, Mansuy D. Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid. Biochemistry 1994;33:166-75
   PubMed Web of Science ®Google Scholar
• Nishiya T, Mori K, Hattori C, The crucial protective role of glutathione against tienilic acid hepatotoxicity in rats. Toxicol Appl Pharmacol 2008;232:280-91
   PubMed Web of Science ®Google Scholar
• Li F, Chordia MD, Woodling KA, Macdonald TL. Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene-S-oxide: a potential model for hepatotoxicity. Chem Res Toxicol 2007;20:1854-61
   PubMed Web of Science ®Google Scholar
• Israel E, Cohn J, Dube L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA 1996;275:931-6
   PubMed Web of Science ®Google Scholar
• Liu MC, Dube LM, Lancaster J, Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6- month randomized multicenter trial. J Allergy Clin Immunol 1996;98:859-71
   PubMed Web of Science ®Google Scholar
• Lazarus SC, Lee T, Kemp JP, Safety and clinical efficacy of zileuton in patients with chronic asthma. Am J Manag Care 1998;4:841-8
   PubMed Web of Science ®Google Scholar
• Nelson H, Kemp J, Berger W, Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study. Ann Allergy Asthma Immunol 2007;99:178-84
   PubMed Web of Science ®Google Scholar
• Wenzel S, Busse W, Calhoun W, The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study. J Asthma 2007;44:305-10
   PubMed Web of Science ®Google Scholar
• Watkins PB, Dube LM, Walton-Bowen K, Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. Drug Saf 2007;30:805-15
   PubMed Web of Science ®Google Scholar
• Dalvie DK, Kalgutkar AS, Khojasteh-Bakht SC, Biotransformation reactions of five-membered aromatic heterocyclic rings. Chem Res Toxicol 2002;15:269-99
   PubMed Web of Science ®Google Scholar
• Mansuy D. Molecular structure and hepatotoxicity: compared data about two closely related thiophene compounds. J Hepatol Suppl 1997;26:22-5
   Google Scholar
• Machinist JM, Mayer MD, Shet MS, Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott- 66193. Drug Metab Dispos 1995;23:1163-74
   PubMed Web of Science ®Google Scholar
• Alvarez FJ, Slade RT. Kinetics and mechanism of degradation of Zileuton, a potent 5-lipoxygenase inhibitor. Pharm Res 1992;9:1465-73
   PubMed Web of Science ®Google Scholar
• Joshi EM, Heasley BH, Chordia MD, Macdonald TL. In Vitro Metabolism of 2-Acetylbenzothiophene: relevance to Zileuton Hepatotoxicity. Chem Res Toxicol 2004;17:137-43
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay U, Biswas K, Banerjee RK. Extrathyroidal actions of antithyroid thionamides. Toxicol Lett 2002;128:117-27
   PubMed Web of Science ®Google Scholar
• Mizutani T, Murakami M, Shirai M, Metabolism-dependent hepatotoxicity of methimazole in mice depleted of glutathione. J Appl Toxicol 1999;19:193-8
   PubMed Web of Science ®Google Scholar
• Poulsen LL, Hyslop RM, Ziegler DM. S oxidation of thioureylenes catalyzed by a microsomal flavoprotein mixed function oxidase. Biochem Pharmacol 1974;23:3431-40
   PubMed Web of Science ®Google Scholar
• Mizutani T, Yoshida K, Murakami M, Evidence for the involvement of N-methylthiourea, a ring cleavage metabolite, in the hepatotoxicity of methimazole in glutathione-depleted mice: structure-toxicity and metabolic studies. Chem Res Toxicol 2000;13:170-6
   PubMed Web of Science ®Google Scholar
• Neal RA, Halpert J. Toxicology of thiono-sulfur compounds. Annu Rev Pharmacol Toxicol 1982;22:321-39
   PubMed Web of Science ®Google Scholar
• Lombardino JG, Wiseman EH. Sudoxicam and related N-heterocyclic carboxamides of 4-hydroxy-2H-1,2-benzothiazine 1,1-dioxide. Potent nonsteroidal antiinflammatory agents. J Med Chem 1972;15:848-9
   PubMed Web of Science ®Google Scholar
• Rostom A, Goldkind L, Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin Gastroenterol Hepatol 2005;3:489-98
   PubMed Web of Science ®Google Scholar
• Obach RS, Kalgutkar AS, Ryder TF, Walker GS. In vitro metabolism and covalent binding of enol-carboxamide derivatives and anti-inflammatory agents sudoxicam and meloxicam: insights into the hepatotoxicity of sudoxicam. Chem Res Toxicol 2008;21:1890-9
   PubMed Web of Science ®Google Scholar
• Cosgrove BD, King BM, Hasan MA, Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol Appl Pharmacol 2009;237:317-30
   PubMed Web of Science ®Google Scholar
• Farid NA, Kurihara A, Wrighton SA. Review: metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 2010;50:126-42
   PubMed Web of Science ®Google Scholar
• Testa L, Bhindi R, Agostoni P, The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile. Expert Opin Drug Saf 2007;6:397-406
   PubMed Web of Science ®Google Scholar
• Wu G, Vashishtha SC, Erve JCL. Characterization of glutathione conjugates of duloxetine by mass spectrometry and evaluation of in silico approaches to rationalize the site of conjugation for thiophene containing drugs. Chem Res Toxicol 2010;23:1393-404
   PubMed Web of Science ®Google Scholar
• Gan J, Ruan Q, He B, In vitro screening of 50 highly prescribed drugs for thiol adduct formation - Comparison of potential for drug-induced toxicity and extent of adduct formation. Chem Res Toxicol 2009;22:690-8
   PubMed Web of Science ®Google Scholar
• Russo MW, Galanko JA, Shrestha R, Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004;10:1018-23
   PubMed Web of Science ®Google Scholar
• Walgren JL, Mitchell MD, Thompson DC. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 2005;35:325-61
   PubMed Web of Science ®Google Scholar
• Seguin B, Uetrecht J. The danger hypothesis applied to idiosyncratic drug reactions. Curr Opin Allergy Clin Immunol 2003;3:235-42
   PubMed Web of Science ®Google Scholar
• Cribb AE, Lee BL, Trepanier LA, Spielberg SP. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev 1996;15:9-50
   PubMed Web of Science ®Google Scholar
• Gruchalla RS. Diagnosis of allergic reactions to sulfonamides. Allergy 1999;54(Suppl 58):28-32
   PubMedGoogle Scholar
• Yu H, Bischoff D, Tweedie D. Challenges and solutions to metabolites in safety testing: impact of the International Conference on Harmonization M3(R2) guidance. Expert Opin Drug Metab Toxicol 2010;6:1539-49
   PubMed Web of Science ®Google Scholar